Peer-Reviewed Articles

Monoclonal Antibodies: Clinical Pharmacology Knowledge in Support of FIH and Early Development

By Narine Baririan, Pharm. D

There are several pharmacokinetic factors and peculiarities that should be considered carefully when designing and running first-in-human (FIH) studies for monoclonal antibodies.

Maximizing Immuno-Oncology Clinical Trial Success

By Luke S. Gill

Cancer immunotherapies require different standards for evaluating their safety and effectiveness. Understanding these standards—and the other major challenges of immuno-oncology studies—is critical to drug development success.

Master Protocols in Oncology: A Review of the Landscape

By Bradley Smith, PhD, Kathy Giusti, MBA, Richard Hamermesh, DBA, Dixie-Lee W. Esseltine, MD

With technology’s increasing ability to gather and analyze previously unmanageable data sets, and medicine’s forays into genomics and targeted therapies, the time of the master protocol may be at hand.

Comply with ICH E6 (R2)

The ICH E6 (R2) GCP Guideline became final in November 2016. As noted in the Guideline, since the original ICH E6 (R1) was released, clinical trials were performed in a largely paper-based process. E6 (R2) was developed to address the increased scale, complexity, and cost of clinical trials, and to include the advances that have been made in electronic data recording and reporting technologies, as well as the implementation of other approaches and, in fact, encourages the implementation of improved and more efficient approaches to clinical trial design, conduct, oversight, recording and reporting while continuing to ensure human subject protection and reliability of trial results.

The articles can help ensure your GCP is up to par in the areas included in the ICH E6 (R2).

Read more.


Patient Perspectives on Seeing Trial Results

The third in a series of results from the Center for Information and Study on Clinical Research Participation’s (CISCRP) landmark 2017 Perceptions & Insights Study.

Patient Input into Leveraging the Healthcare Professional’s Role

The second series of findings from CISCRP's 2017 Perceptions & Insights Study.

Public Clinical Research Literacy: New Insights

The first series of results from CISCRP's 2017 Perceptions & Insights Study.



BIO International Convention

June 04 - 07, 2018
Boston, MA

American Biomanufacturing Summit 2018

June 14 - August 15, 2018
Hyatt Regency San Francisco Airport, San Francisco, CA

7th Annual Publication and Clinical Trial Transparency

June 20 - 21, 2018
Amsterdam, The Netherlands


CRA Skills Lacking in Critical Areas

By Moe Alsumidaie

A global CRO’s data gathered using an objective monitoring simulation administered by CRA Assessments, LLC reveals that CRAs are consistently underperforming regardless of the level of experience or training.

New Weapons and new Warnings Over Health Research

By Peter O'Donnell

Artificial intelligence is a "new weapon" in healthcare research.

Gene Therapy in Rare Diseases: Home and Dosing Site Considerations

By Mariah Baltezegar

With the rise in gene therapies entering clinical trials, it is important to address the operational challenges associated with these types of trials.


Setting up a Central Lab for a Clinical Trial

By Victor Muts, PhD

When less is more. Using three referral labs vs. one central lab.

EMA’s Demands for Plain-Language Summaries for Clinical Trial Results that can be Understood by Anyone Could Create new Challenges for Sponsors

By Pooja Phogat, Vidhi Vashisht

From 2019, to comply with requirements for greater transparency around clinical research as part of the EU Clinical Trials Regulation 536/2014, life sciences firms will be expected to prepare plain-language summaries for all Phase I through IV interventional trials, which can be understood by patients, the general public, and experts.


Clinical Trials for Rare Diseases

This eBook will focus on advancing research, drug development, and trial management in rare diseases. Articles cover considerations from virtual trials and eCOA to the case for highly-skilled CRAs.

View all eBooks


lorem ipsum